Figure 3.

Overall survival of patients treated on TT and non-TT protocols from the time of relapse according to the presence or absence of cytogenetic abnormalities (CA) at baseline or relapse. Superior post-transplant survival was observed in patients lacking CA at both time-points, followed by patients with CA at baseline only, whereas those with CA pre-transplant fared poorly regardless of baseline CA status.